Rutgers, the State University of New Jersey

Albert Einstein College of Medicine

Phri Properties, Inc.

The Public Health Research Institute of the City of New York, Inc.

David Alland

Soumitesh Chakravorty

Fred Russell Kramer

Sanjay Tyagi

Barry R Bloom

William R Jacobs, Jr

Joel S Freundlich

Sean Ekins

Glenn Capodagli

Matthew B Neiditch

Divya Awasthi

Pradeep Kumar

Jacqueline Vet

Amy Piatek

Igor Kramnik

The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes infor identifying the presence ofDNA and/or resistance to anti-tuberculosis drugs.

Polymerase chain reaction primers and probes for

The invention provides compounds of formula I: and salts thereof wherein R-Rhave any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Therapeutic indazoles

This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistantin a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistantin a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wild-type RRDR indicates the presence of rifampicin resistantin the sample.

Detection of drug resistant mycobacterium tuberculosis

The invention provides compounds of formula (I): and salts thereof wherein R-Rhave any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis). 

The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes infor identifying the presence of M.tb DNA and/or resistance to anti-tuberculosis drugs.

Detection of drug resistant

This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistantin a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistantin a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wildtype RRDR indicates the presence of rifampicin resistantin the sample.

[object Object]

The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes.

Assays for short sequence variants

The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterial gene) in a sample using a pool (e.g., 2, 3, 4, or more) of oligonucleotide hybridization probes.

This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against using induction of the iniB promoter.

IniB, iniA and iniC genes of mycobacteria and methods of use

Non-competitive, quantitative amplification assay methods, including assays employing amplification by the polymerase chain reaction (PCR) process, for accurately measuring levels of target nucleic acid and sequences in samples and for ascertaining the relative amounts of cross-hybridizing alleles and mutants.

Non-competitive co-amplification methods

The method provided by the present invention sets forth a novel combination of methods and principles which allows for the rapid and accurate isolation and identification of a large number of differentially expressed mRNAs.

Method of identification of differentially expressed MRNA

This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against,using induction of the iniB promoter.

Growing community of inventors

Bernardsville, NJ, United States of America

David Alland